Database Query Results : , , TrxR

TrxR, Thioredoxin Reductase: Click to Expand ⟱
Source:
Type:
TrxR is an enzyme that reduces Trx, allowing it to perform its reducing functions. It has been shown to have a role in cancer cell metabolism and survival.
TrxR is overexpressed in various types of cancer, including breast, lung, colon, and prostate cancer.

- Part of the thioredoxin system, which regulates reactive oxygen species (ROS).
- TrxR is a major antioxidant systems that maintains the intracellular redox homeostasis.
- Inhibition causes an increase in ROS.
- TrxR is often upregulated in cancer cells to help manage increased oxidative stress, it is seen as a potential therapeutic target. Inhibiting TrxR may result in increased ROS in cancer cells, pushing them toward apoptosis.
- TrxR is a selenoprotein—meaning it incorporates the trace element selenium in the form of the amino acid selenocysteine.

TrxR inhibitors:
-Piperlongumine
-Withania somnifera (Ashwagandha)
-Parthenolide
-EGCG
-Curcumin
-Myricetin
-Gambogic Acid
Scientific Papers found: Click to Expand⟱
1361- Ash,  SRF,    Withaferin A, a natural thioredoxin reductase 1 (TrxR1) inhibitor, synergistically enhances the antitumor efficacy of sorafenib through ROS-mediated ER stress and DNA damage in hepatocellular carcinoma cells
- in-vitro, Liver, HUH7 - in-vivo, Liver, HUH7
TrxR↓, ROS↑, DNA-PK↑, ER Stress↑, Apoptosis↑, eff↓,
1900- Aur,    Potential Anticancer Activity of Auranofin
- Review, Var, NA
TrxR↓, ROS↑, Apoptosis↓, TumCP↓, eff↑,
2617- Ba,    Potential of baicalein in the prevention and treatment of cancer: A scientometric analyses based review
- Review, Var, NA
Ca+2↑, MMP2↓, MMP9↓, Vim↓, Snail↓, E-cadherin↑, Wnt↓, β-catenin/ZEB1↓, p‑Akt↓, p‑mTOR↓, NF-kB↓, i-ROS↑, Bcl-2↓, BAX↑, Cyt‑c↑, Casp3↑, Casp9↑, STAT3↓, IL6↓, MMP2↓, MMP9↓, NOTCH↓, PPARγ↓, p‑NRF2↓, HK2↓, LDHA↓, PDK1↓, Glycolysis↓, PTEN↑, Akt↓, Hif1a↓, MMP↓, VEGF↓, VEGFR2↓, TOP2↓, uPA↓, TIMP1↓, TIMP2↓, cMyc↓, TrxR↓, ASK1↑, Vim↓, ZO-1↑, E-cadherin↑, SOX2↓, OCT4↓, Shh↓, Smo↓, Gli1↓, N-cadherin↓, XIAP↓,
2806- CHr,  Se,    Selenium-containing chrysin and quercetin derivatives: attractive scaffolds for cancer therapy
- in-vitro, Var, NA
eff↑, selectivity↑, Dose↝, TrxR↓, GSH↓, MMP↓, ROS↑, H2O2↑,
1977- CUR,    Synthesis and evaluation of curcumin analogues as potential thioredoxin reductase inhibitors
- in-vitro, BC, MCF-7 - in-vitro, Cerv, HeLa - in-vitro, Lung, A549
TrxR↓, Dose↝, eff↑,
1982- CUR,    Inhibition of thioredoxin reductase by curcumin analogs
- in-vitro, NA, NA
eff↑, TrxR↓,
1979- CUR,  Rad,    Dimethoxycurcumin, a metabolically stable analogue of curcumin enhances the radiosensitivity of cancer cells: Possible involvement of ROS and thioredoxin reductase
- in-vitro, Lung, A549
eff↑, ROS↑, GSH/GSSG↓, TrxR↓, selectivity↑,
1980- CUR,  Rad,    Thioredoxin reductase-1 (TxnRd1) mediates curcumin-induced radiosensitization of squamous carcinoma cells
- in-vitro, Cerv, HeLa - in-vitro, Laryn, FaDu
selectivity↑, RadioS↑, TrxR↓, ROS↑, ERK↑, Dose∅, cl‑PARP↑,
1981- CUR,    Mitochondrial targeted curcumin exhibits anticancer effects through disruption of mitochondrial redox and modulation of TrxR2 activity
- in-vitro, Lung, NA
eff↑, ROS↑, mt-GSH↓, Bax:Bcl2↑, Cyt‑c↑, MMP↓, Casp3↑, Trx2↓, TrxR↓, mt-DNAdam↑,
642- EGCG,    Prooxidant Effects of Epigallocatechin-3-Gallate in Health Benefits and Potential Adverse Effect
ROS↑, H2O2↑, Apoptosis↑, Trx↓, TrxR↓, JNK↑, HO-1↑, Fenton↑,
1975- EGCG,    Molecular bases of thioredoxin and thioredoxin reductase-mediated prooxidant actions of (-)-epigallocatechin-3-gallate
- in-vitro, Cerv, HeLa
TrxR↓, Trx↓, ROS↑, Dose↑,
1954- GamB,    Gambogic acid induces apoptosis in hepatocellular carcinoma SMMC-7721 cells by targeting cytosolic thioredoxin reductase
- in-vitro, HCC, SMMC-7721 cell
AntiTum↑, TrxR↓, TrxR1↓, ROS↑, Apoptosis↑, Dose∅, Dose?,
1955- GamB,    Gambogic acid inhibits thioredoxin activity and induces ROS-mediated cell death in castration-resistant prostate cancer
- in-vitro, Pca, NA
ROS↑, Apoptosis↑, Ferroptosis↑, Trx↓, eff↑, TrxR↓, Dose∅, MMP↓, eff↑,
1901- GoldNP,  Rad,    The role of thioredoxin reductase in gold nanoparticle radiosensitization effects
- in-vitro, Lung, A549
MMP↓, ROS↑, RadioS↑, TrxR↓,
1904- GoldNP,  SNP,    Unveiling the Potential of Innovative Gold(I) and Silver(I) Selenourea Complexes as Anticancer Agents Targeting TrxR and Cellular Redox Homeostasis
- in-vitro, Lung, H157 - in-vitro, BC, MCF-7 - in-vitro, Colon, HCT15 - in-vitro, Melanoma, A375
TrxR↓, selectivity↑, eff↑, eff↝, ROS↑, MMP↓, Apoptosis↑, eff↑,
1998- Myr,  CUR,    Thioredoxin-dependent system. Application of inhibitors
- Review, Var, NA
TrxR↓, ROS↑,
1997- Myr,  QC,    Inhibition of Mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity
- in-vitro, Lung, A549
TrxR↓, eff↑, TumCCA↑, eff↓, ROS↑,
1983- Part,    Targeting thioredoxin reductase by micheliolide contributes to radiosensitizing and inducing apoptosis of HeLa cells
- in-vitro, Cerv, HeLa
eff↑, TrxR↓, ROS↑, RadioS↑,
1946- PL,  PI,    Piperlonguminine and Piperine Analogues as TrxR Inhibitors that Promote ROS and Autophagy and Regulate p38 and Akt/mTOR Signaling
- in-vitro, Liver, NA
eff↑, toxicity↓, TrxR↓, ROS↑, MMP↓, p38↑, Akt↓, mTOR↓,
1949- PL,    Design, synthesis, and biological evaluation of a novel indoleamine 2,3-dioxigenase 1 (IDO1) and thioredoxin reductase (TrxR) dual inhibitor
- in-vitro, CRC, HCT116 - in-vitro, Cerv, HeLa
TrxR↓, selectivity↑, ROS↑, IDO1↓,
1951- PL,    Piperlongumine Analogs Promote A549 Cell Apoptosis through Enhancing ROS Generation
- in-vitro, Lung, A549
ROS↑, lipid-P↑, MMP↓, TumCCA↑, TrxR↓, eff↑,
1952- PL,  5-FU,    Piperlongumine induces ROS accumulation to reverse resistance of 5-FU in human colorectal cancer via targeting TrxR
- in-vivo, CRC, HCT8
ROS↑, TrxR↓, eff↑, p‑Akt↓,
1953- PL,    Designing piperlongumine-directed anticancer agents by an electrophilicity-based prooxidant strategy: A mechanistic investigation
- in-vitro, Lung, A549 - in-vitro, Nor, WI38
ROS↑, selectivity↑, TrxR↓, TumCCA↑, GSH?, H2O2↑,
2948- PL,    The promising potential of piperlongumine as an emerging therapeutics for cancer
- Review, Var, NA
tumCV↓, TumCP↓, TumCI↓, angioG↓, EMT↓, TumMeta↓, *hepatoP↑, *lipid-P↓, *GSH↑, cardioP↑, CycB/CCNB1↓, cycD1/CCND1↓, CDK2↓, CDK1↓, CDK4↓, CDK6↓, PCNA↓, Akt↓, mTOR↓, Glycolysis↓, NF-kB↓, IKKα↓, JAK1↓, JAK2↓, STAT3↓, ERK↓, cFos↓, Slug↓, E-cadherin↑, TOP2↓, P53↑, P21↑, Bcl-2↓, BAX↑, Casp3↑, Casp7↑, Casp8↑, p‑HER2/EBBR2↓, HO-1↑, NRF2↑, BIM↑, p‑FOXO3↓, Sp1/3/4↓, cMyc↓, EGFR↓, survivin↓, cMET↓, NQO1↑, SOD2↑, TrxR↓, MDM2↓, p‑eIF2α↑, ATF4↑, CHOP↑, MDA↑, Ki-67↓, MMP9↓, Twist↓, SOX2↓, Nanog↓, OCT4↓, N-cadherin↓, Vim↓, Snail↓, TumW↓, TumCG↓, HK2↓, RB1↓, IL6↓, IL8↓, SOD1↑, RadioS↑, ChemoSen↑, toxicity↓, Sp1/3/4↓, GSH↓, SOD↑,
2946- PL,    Piperlongumine, a potent anticancer phytotherapeutic: Perspectives on contemporary status and future possibilities as an anticancer agent
- Review, Var, NA
ROS↑, GSH↓, DNAdam↑, ChemoSen↑, RadioS↑, BioEnh↑, selectivity↑, BioAv↓, eff↑, p‑Akt↓, mTOR↓, GSK‐3β↓, β-catenin/ZEB1↓, HK2↓, Glycolysis↓, Cyt‑c↑, Casp9↑, Casp3↑, Casp7↑, cl‑PARP↑, TrxR↓, ER Stress↑, ATF4↝, CHOP↑, Prx4↑, NF-kB↓, cycD1/CCND1↓, CDK4↓, CDK6↓, p‑RB1↓, RAS↓, cMyc↓, TumCCA↑, selectivity↑, STAT3↓, NRF2↑, HO-1↑, PTEN↑, P-gp↓, MDR1↓, MRP1↓, survivin↓, Twist↓, AP-1↓, Sp1/3/4↓, STAT1↓, STAT6↓, SOX4↑, XBP-1↑, P21↑, eff↑, Inflam↓, COX2↓, IL6↓, MMP9↓, TumMeta↓, TumCI↓, ICAM-1↓, CXCR4↓, VEGF↓, angioG↓, Half-Life↝, BioAv↑,
2942- PL,    Piperlongumine increases sensitivity of colorectal cancer cells to radiation: Involvement of ROS production via dual inhibition of glutathione and thioredoxin systems
- in-vitro, CRC, CT26 - in-vitro, CRC, DLD1 - in-vivo, CRC, CT26
ROS↑, GSH↓, TrxR↓, RadioS↑, DNAdam↑, TumCCA↑, mitResp↓, GSTs↓, OS↑,
2649- PL,    Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence
- Review, Var, NA
AntiCan↑, ROS↑, GSH↓, TrxR↓, Trx↓, Apoptosis↑, TumCCA↑, ER Stress↑, DNAdam↑, ChemoSen↑, BioAv↓,
2962- PL,    Synthesis of Piperlongumine Analogues and Discovery of Nuclear Factor Erythroid 2‑Related Factor 2 (Nrf2) Activators as Potential Neuroprotective Agents
- in-vitro, Nor, PC12
*GSH↑, *NQO1↑, *Trx↑, *TrxR↑, *NRF2↑, *NRF2⇅, *eff↑, *BioAv↑, *ROS↓,
2651- Plum,    Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence
- Review, Var, NA
ROS↑, TrxR↓, GSR↓, ER Stress↓, TumCCA↑, MMP↓, NF-kB↓, PI3K↓, Akt↓, mTOR↓, MKP1↓, MKP2↓, ChemoSen↑,
4717- Se,    A systematic review of Selenium as a complementary treatment in cancer patients
- Review, Var, NA
*antiOx↑, eff↝, radioP↑, chemoP↑, *selenoP↑, *GPx↑, TrxR↑, *ROS↓,
4485- Se,    Selenium stimulates the antitumour immunity: Insights to future research
- Review, NA, NA
*antiOx↑, chemoPv↑, ROS↑, Imm↑, selenoP↑, *IL2↑, *IL4↑, *TNF-α↓, *TGF-β↓, *EMT↓, Risk↓, *GPx↑, *TrxR↑,
3663- SFN,    Efficacy of Sulforaphane in Neurodegenerative Diseases
- Review, AD, NA - Review, Park, NA
*antiOx↑, *Inflam↓, *Half-Life↝, *NRF2↑, *NQO1↑, *HO-1↑, *TrxR↑, *ROS↓, *TNF-α↓, *IL1β↓, *IL6↓, *iNOS↓, *COX2↓, *Aβ↓, *GSH↑, *cognitive↑, *BACE↓, *HSP70/HSPA5↑, *neuroP↑, *ROS↓, *BBB↑, *MMP9↓,
3658- SFN,    Pre-Clinical Neuroprotective Evidences and Plausible Mechanisms of Sulforaphane in Alzheimer’s Disease
- Review, AD, NA
*NRF2↑, *antiOx↑, *neuroP↑, *Aβ↓, *BACE↓, *NQO1↑, *IL1β↓, *TNF-α↓, *IL6↓, *COX2↓, *iNOS↓, *NF-kB↓, *NLRP3↓, *Ca+2↓, *GSH↑, *MDA↓, *ROS↓, *SOD↑, *HO-1↑, *TrxR↑, *cognitive↑, *tau↓, *HSP70/HSPA5↑,
1459- SFN,  Aur,    Auranofin Enhances Sulforaphane-Mediated Apoptosis in Hepatocellular Carcinoma Hep3B Cells through Inactivation of the PI3K/Akt Signaling Pathway
- in-vitro, Liver, Hep3B - in-vitro, Liver, HepG2
eff↑, TumCCA↑, Apoptosis↑, MMP↓, BAX↑, cl‑PARP↑, Casp3↑, Casp8↑, Casp9↑, ROS↑, eff↓, PI3K↓, Akt↓, TrxR↓, BAX↑, Bcl-2∅,
3041- SK,    Promising Nanomedicines of Shikonin for Cancer Therapy
- Review, Var, NA
Glycolysis↓, TAMS↝, BioAv↓, Half-Life↝, P21↑, ERK↓, ROS↑, GSH↓, MMP↓, TrxR↓, MMP13↓, MMP2↓, MMP9↓, SIRT2↑, Hif1a↓, PKM2↓, TumCP↓, TumMeta↓, TumCI↓,
1903- SNP,    Novel Silver Complexes Based on Phosphanes and Ester Derivatives of Bis(pyrazol-1-yl)acetate Ligands Targeting TrxR: New Promising Chemotherapeutic Tools Relevant to SCLC Managemen
- in-vitro, Lung, U1285
TrxR↓, eff↝, ROS↑,
1906- SNP,  GoldNP,  Cu,    Current Progresses in Metal-based Anticancer Complexes as Mammalian TrxR Inhibitors
- Review, Var, NA
TrxR↓, eff↓, eff↓,
1905- SNP,    Evaluation of the effect of silver and silver nanoparticles on the function of selenoproteins using an in-vitro model of the fish intestine: The cell line RTgutGC
- in-vivo, Nor, NA
*TrxR↓, *ROS∅, GPx↑,
1902- SNP,    Modulation of the mechanism of action of antibacterial silver N-heterocyclic carbene complexes by variation of the halide ligand
- in-vitro, NA, NA
TrxR↓, GSR↓, GSH↓,
1907- SNP,  GoldNP,  Cu,    In vitro antitumour activity of water soluble Cu(I), Ag(I) and Au(I) complexes supported by hydrophilic alkyl phosphine ligands
- in-vitro, Lung, A549 - in-vitro, BC, MCF-7 - in-vitro, Melanoma, A375 - in-vitro, Colon, HCT15 - in-vitro, Cerv, HeLa
TrxR↓, eff↓, eff↓, other∅,
1908- SNP,    Exposure to Silver Nanoparticles Inhibits Selenoprotein Synthesis and the Activity of Thioredoxin Reductase
- in-vitro, Lung, A549
TrxR↓, TrxR1↓, ROS↑, ER Stress↑, TumCP↓, selenoP↓,
1909- SNP,    The Antibacterial Drug Candidate SBC3 is a Potent Inhibitor of Bacterial Thioredoxin Reductase
- in-vivo, Nor, NA
TrxR↓,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 42

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned ⓘ

chemoPv↑, 1,  

Redox & Oxidative Stress ⓘ

Fenton↑, 1,   Ferroptosis↑, 1,   GPx↑, 1,   GSH?, 1,   GSH↓, 7,   mt-GSH↓, 1,   GSH/GSSG↓, 1,   GSR↓, 2,   GSTs↓, 1,   H2O2↑, 3,   HO-1↑, 3,   lipid-P↑, 1,   MDA↑, 1,   NQO1↑, 1,   NRF2↑, 2,   p‑NRF2↓, 1,   Prx4↑, 1,   ROS↑, 29,   i-ROS↑, 1,   selenoP↓, 1,   selenoP↑, 1,   SOD↑, 1,   SOD1↑, 1,   SOD2↑, 1,   Trx↓, 4,   Trx2↓, 1,   TrxR↓, 36,   TrxR↑, 1,   TrxR1↓, 2,  

Mitochondria & Bioenergetics ⓘ

mitResp↓, 1,   MMP↓, 11,   XIAP↓, 1,  

Core Metabolism/Glycolysis ⓘ

cMyc↓, 3,   Glycolysis↓, 4,   HK2↓, 3,   IDO1↓, 1,   LDHA↓, 1,   PDK1↓, 1,   PKM2↓, 1,   PPARγ↓, 1,   SIRT2↑, 1,  

Cell Death ⓘ

Akt↓, 5,   p‑Akt↓, 3,   Apoptosis↓, 1,   Apoptosis↑, 7,   ASK1↑, 1,   BAX↑, 4,   Bax:Bcl2↑, 1,   Bcl-2↓, 2,   Bcl-2∅, 1,   BIM↑, 1,   Casp3↑, 5,   Casp7↑, 2,   Casp8↑, 2,   Casp9↑, 3,   Cyt‑c↑, 3,   Ferroptosis↑, 1,   JNK↑, 1,   MDM2↓, 1,   MKP1↓, 1,   MKP2↓, 1,   p38↑, 1,   survivin↓, 2,  

Kinase & Signal Transduction ⓘ

p‑HER2/EBBR2↓, 1,   Sp1/3/4↓, 3,  

Transcription & Epigenetics ⓘ

other∅, 1,   tumCV↓, 1,  

Protein Folding & ER Stress ⓘ

CHOP↑, 2,   p‑eIF2α↑, 1,   ER Stress↓, 1,   ER Stress↑, 4,   XBP-1↑, 1,  

DNA Damage & Repair ⓘ

DNA-PK↑, 1,   DNAdam↑, 3,   mt-DNAdam↑, 1,   P53↑, 1,   cl‑PARP↑, 3,   PCNA↓, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 1,   CDK2↓, 1,   CDK4↓, 2,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 2,   P21↑, 3,   RB1↓, 1,   p‑RB1↓, 1,   TumCCA↑, 8,  

Proliferation, Differentiation & Cell State ⓘ

cFos↓, 1,   cMET↓, 1,   EMT↓, 1,   ERK↓, 2,   ERK↑, 1,   p‑FOXO3↓, 1,   Gli1↓, 1,   GSK‐3β↓, 1,   mTOR↓, 4,   p‑mTOR↓, 1,   Nanog↓, 1,   NOTCH↓, 1,   OCT4↓, 2,   PI3K↓, 2,   PTEN↑, 2,   RAS↓, 1,   Shh↓, 1,   Smo↓, 1,   SOX2↓, 2,   STAT1↓, 1,   STAT3↓, 3,   STAT6↓, 1,   TOP2↓, 2,   TumCG↓, 1,   Wnt↓, 1,  

Migration ⓘ

AP-1↓, 1,   Ca+2↑, 1,   E-cadherin↑, 3,   Ki-67↓, 1,   MMP13↓, 1,   MMP2↓, 3,   MMP9↓, 5,   N-cadherin↓, 2,   Slug↓, 1,   Snail↓, 2,   SOX4↑, 1,   TIMP1↓, 1,   TIMP2↓, 1,   TumCI↓, 3,   TumCP↓, 4,   TumMeta↓, 3,   Twist↓, 2,   uPA↓, 1,   Vim↓, 3,   ZO-1↑, 1,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature ⓘ

angioG↓, 2,   ATF4↑, 1,   ATF4↝, 1,   EGFR↓, 1,   Hif1a↓, 2,   TAMS↝, 1,   VEGF↓, 2,   VEGFR2↓, 1,  

Barriers & Transport ⓘ

P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   CXCR4↓, 1,   ICAM-1↓, 1,   IKKα↓, 1,   IL6↓, 3,   IL8↓, 1,   Imm↑, 1,   Inflam↓, 1,   JAK1↓, 1,   JAK2↓, 1,   NF-kB↓, 4,  

Hormonal & Nuclear Receptors ⓘ

CDK6↓, 2,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 3,   BioAv↑, 1,   BioEnh↑, 1,   ChemoSen↑, 4,   Dose?, 1,   Dose↑, 1,   Dose↝, 2,   Dose∅, 3,   eff↓, 7,   eff↑, 18,   eff↝, 3,   Half-Life↝, 2,   MDR1↓, 1,   MRP1↓, 1,   RadioS↑, 6,   selectivity↑, 8,  

Clinical Biomarkers ⓘ

EGFR↓, 1,   p‑HER2/EBBR2↓, 1,   IL6↓, 3,   Ki-67↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   AntiTum↑, 1,   cardioP↑, 1,   chemoP↑, 1,   OS↑, 1,   radioP↑, 1,   Risk↓, 1,   toxicity↓, 2,   TumW↓, 1,  
Total Targets: 184

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 4,   GPx↑, 2,   GSH↑, 4,   HO-1↑, 2,   lipid-P↓, 1,   MDA↓, 1,   NQO1↑, 3,   NRF2↑, 3,   NRF2⇅, 1,   ROS↓, 5,   ROS∅, 1,   selenoP↑, 1,   SOD↑, 1,   Trx↑, 1,   TrxR↓, 1,   TrxR↑, 4,  

Cell Death ⓘ

iNOS↓, 2,  

Protein Folding & ER Stress ⓘ

HSP70/HSPA5↑, 2,  

Proliferation, Differentiation & Cell State ⓘ

EMT↓, 1,  

Migration ⓘ

Ca+2↓, 1,   MMP9↓, 1,   TGF-β↓, 1,  

Barriers & Transport ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 2,   IL1β↓, 2,   IL2↑, 1,   IL4↑, 1,   IL6↓, 2,   Inflam↓, 1,   NF-kB↓, 1,   TNF-α↓, 3,  

Synaptic & Neurotransmission ⓘ

tau↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 2,   BACE↓, 2,   NLRP3↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 1,   eff↑, 1,   Half-Life↝, 1,  

Clinical Biomarkers ⓘ

IL6↓, 2,  

Functional Outcomes ⓘ

cognitive↑, 2,   hepatoP↑, 1,   neuroP↑, 2,  
Total Targets: 42

Scientific Paper Hit Count for: TrxR, Thioredoxin Reductase
10 Piperlongumine
8 Silver-NanoParticles
6 Curcumin
4 Gold NanoParticles
3 Selenium
3 Radiotherapy/Radiation
3 Sulforaphane (mainly Broccoli)
2 Auranofin
2 EGCG (Epigallocatechin Gallate)
2 Gambogic Acid
2 Myricetin
2 Copper and Cu NanoParticlex
1 Ashwagandha(Withaferin A)
1 Sorafenib (brand name Nexavar)
1 Baicalein
1 Chrysin
1 Quercetin
1 Parthenolide
1 Piperine
1 5-fluorouracil
1 Plumbagin
1 Shikonin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:825  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page